# A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

> **NCT02730481** · PHASE1 · COMPLETED · sponsor: **Athenex, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Oraxol

## Key facts

- **NCT ID:** NCT02730481
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-03
- **Final completion:** 2021-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730481, "A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02730481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*